Loading clinical trials...

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE4

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

A Prospective, Open-Label Study to Evaluate Subject Satisfaction With Overall Facial Appearance After Treatment With JUVÉDERM® Products in Medical Weight Loss (MWL) Subjects

NCT07186595•AbbVie

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.

Eligibility

Age

22 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Must meet at least 3 of the following criteria for treatment in the face with at least 2 JUVÉDERM products, per investigator's assessment:
•* Minimal, moderate, or severe on Allergan Temple Hollowing Scale (ATHS)
•* Moderate or severe for both eyes on Allergan Infraorbital Hollow Scale (AIHS)
•* Moderate or severe on Allergan Cheek Smoothness Scale (ACSS)
•* Moderate, significant, or severe on Mid-face Volume Deficit Scale (MFVDS)
•* Moderate or severe on Nasolabial Fold Severity Scale (NLFSS)
•* Minimal, mild, or moderate on Allergan Lip Fullness Scale 2 (ALFS2)
•* Moderate or severe on Allergan Chin Retrusion Scale (ACRS)
•* Moderate or severe on Allergan Loss of Jawline Definition Scale (ALJDS)
•Must be in good health as determined by subject's medical history, physical examination, and vital sign measurements.

Exclusion Criteria

•Prior treatment with non-permanent soft tissue fillers or fat-reducing injectables in the face or neck within 12 months prior to screening.
•Excessively loose skin in the face and/or neck.
•Tendency to develop hypertrophic scarring and/or keloid scarring.

Locations (10)

Kian Aesthetic Institute /ID# 277045

Los Angeles, California, United States

West Dermatology La Jolla /ID# 277034

San Diego, California, United States

Pacific Clinical Innovations /ID# 277026

Vista, California, United States

Skin Research Institute LLC /ID# 277038

Coral Gables, Florida, United States

Monarch Plastic Surgery and Skin Renewal Center /ID# 278182

Atlanta, Georgia, United States

Advanced Dermatology - Lincolnshire /ID# 277036

Lincolnshire, Illinois, United States

H&H Research, LLC /ID# 277084

Metairie, Louisiana, United States

DelRicht Research - New Orleans 308 /ID# 277039

New Orleans, Louisiana, United States

Bellaire Dermatology Associates /ID# 278180

Bellaire, Texas, United States

SkinDC /ID# 277062

Arlington, Virginia, United States

Key Dates

Start Date

September 25, 2025

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

February 23, 2026

Enrollment

ACTUAL participants

Conditions

Mid Face Volume Deficit

Interventions

JUVÉDERM VOLUX XC

DEVICE

JUVÉDERM VOLUMA XC

DEVICE

JUVÉDERM VOLBELLA XC

DEVICE

JUVÉDERM VOLLURE XC

DEVICE

SKINVIVE by JUVÉDERM

DEVICE

JUVÉDERM ULTRA XC

DEVICE

JUVÉDERM ULTRA PLUS XC

DEVICE

A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

NCT05452070

Mid Face Volume Deficit

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions